Dr. Chris Parker: Radium-223 in Prostate Cancer Is a Landmark Finding
Dr. Chris Parker: Radium-223 in Prostate Cancer Is a Landmark Finding
Chris Parker, MD
20111017
2011 Nov 17
Interview by L Scott Zoeller
Dr. Chris Parker: Radium-223 in Prostate Cancer Is a Landmark Finding
Interview by L Scott Zoeller. 2011 Nov 17, Chris Parker, MD
To mark 2011, we have asked our distinguished OncologySTAT Advisory Board Members to choose their top story of the year. Dr. Chris Parker discusses his choice for the year’s most important development in prostate cancer research. OncologySTAT: In your view, which development in 2011 in prostate cancer could have the most significant impact in oncology?Dr. Parker: Radium-223, a bone-seeking, alpha-emitting radioisotope, has been shown to improve overall survival in men with bone metastases from advanced...
Meet Our Experts
Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.
